Is Any Cardiovascular Disease-Specific DNA Methylation Biomarker Within Reach?
PURPOSE OF REVIEW: A detailed understanding of the epigenome of cardiovascular disease (CVD) should broaden current insights into mechanisms of atherogenesis and help identify suitable biomarkers for disease risk and progression. This review addresses the question whether a consensus has been reached on identifying the main aberrant DNA methylation profile in CVD. Additionally, it presents advances and setbacks in the search for specific CVD biomarkers.
RECENT FINDINGS: Although the literature points to DNA hypermethylation as an epigenetic landmark of CVD, inconsistencies are significant. In particular, the DNA methylomes of peripheral blood cells and the vascular wall do not show a consistent direction of change in all studies. An additional significant hurdle is the relatively low study-to-study reproducibility and the difficulty to assess specificity for CVD. Nonetheless, a number of biologically plausible markers have been proposed that warrant further studies. An integrated model for dynamic changes of DNA methylation during the natural history of atherosclerosis predisposition and progression is presented, that might reconcile conflicting findings. Cohort design and technical criteria for DNA methylation analysis need to be further homogenized to allow for meaningful validation. As stable DNA methylation profiles are likely determined by genetic variants, many of which might control a range of diseases, it is anticipated that CVD biomarker discovery will be a delicate balancing act between reproducibility and specificity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Current atherosclerosis reports - 22(2020), 10 vom: 26. Aug., Seite 62 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de la Rocha, Carmen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Completed 19.01.2021 Date Revised 19.01.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11883-020-00875-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314176403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314176403 | ||
| 003 | DE-627 | ||
| 005 | 20231225152154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11883-020-00875-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314176403 | ||
| 035 | |a (NLM)32844297 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de la Rocha, Carmen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is Any Cardiovascular Disease-Specific DNA Methylation Biomarker Within Reach? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2021 | ||
| 500 | |a Date Revised 19.01.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE OF REVIEW: A detailed understanding of the epigenome of cardiovascular disease (CVD) should broaden current insights into mechanisms of atherogenesis and help identify suitable biomarkers for disease risk and progression. This review addresses the question whether a consensus has been reached on identifying the main aberrant DNA methylation profile in CVD. Additionally, it presents advances and setbacks in the search for specific CVD biomarkers | ||
| 520 | |a RECENT FINDINGS: Although the literature points to DNA hypermethylation as an epigenetic landmark of CVD, inconsistencies are significant. In particular, the DNA methylomes of peripheral blood cells and the vascular wall do not show a consistent direction of change in all studies. An additional significant hurdle is the relatively low study-to-study reproducibility and the difficulty to assess specificity for CVD. Nonetheless, a number of biologically plausible markers have been proposed that warrant further studies. An integrated model for dynamic changes of DNA methylation during the natural history of atherosclerosis predisposition and progression is presented, that might reconcile conflicting findings. Cohort design and technical criteria for DNA methylation analysis need to be further homogenized to allow for meaningful validation. As stable DNA methylation profiles are likely determined by genetic variants, many of which might control a range of diseases, it is anticipated that CVD biomarker discovery will be a delicate balancing act between reproducibility and specificity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a Differentially methylated region | |
| 650 | 4 | |a Epigenomics | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Zaina, Silvio |e verfasserin |4 aut | |
| 700 | 1 | |a Lund, Gertrud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current atherosclerosis reports |d 1999 |g 22(2020), 10 vom: 26. Aug., Seite 62 |w (DE-627)NLM110370473 |x 1534-6242 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:10 |g day:26 |g month:08 |g pages:62 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11883-020-00875-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 10 |b 26 |c 08 |h 62 | ||